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1. Introduction 
One of the great challenges of modern molecular biology is the integration of new genetic 
information into procedures that can be implemented in rapid, cost effective and reliable 
methods to genotype, phenotype, identify gene function, and development treatment for the 
disease. One of the major impacts of such methods and procedures is the increase of our 
knowledge and understanding of human biology leading to the recognition of the 
importance of molecular factors in disease aetiology. The immediate consequence of such 
knowledge is an increased ability for pathology diagnostic and for the identification of pre-
symptomatic individuals or those susceptible to specific diseases, improving our ability for 
disease prognosis and to develop more efficient therapeutic strategies.  
Every organism is exposed to hazardous agents in its environment on a continual basis.  As a 
result, organisms have evolved sophisticated pathways that are considered an environmental 
response machinery, to minimize the biological consequences of hazardous environmental 
agents.  A large number of human genes, including the ones involved in the environmental 
response machinery, are subject to genetic variability, which can be associated with the altered 
efficiency of a biological pathway (Perera & Weinstein, 2000). So, an individual’s risk for 
developing a disease stemming from an environmental exposure might be dependent on the 
efficiency of his/her own unique set of environmental response genes. These genes are usually 
involved in the metabolism of environmental carcinogens, in the repair of DNA lesions 
induced by exogenous and endogenous carcinogens, and in the control of the cell cycle. 
Individual polymorphic forms in those genes have been associated with individual 
susceptibility to different types of cancer  namely in breast and thyroid cancer (Conde et al., 
2009; Gaspar et al., 2004; Pabalan et al., 2010; Peng et al., 2011; Silva et al., 2005; Silva et al., 
2006b; Silva et al., 2006a; Silva et al., 2009; Silva et al., 2010; Silva et al., 2007).  
Several enzymes have evolved for the detoxification of xenobiotic compounds, and their 
gene expression is induced in response to the presence of numerous compounds (e.g., 
polycyclic aromatic hydrocarbons found in tobacco smoke). An inefficient detoxification of 
reactive endogenous or exogenous compounds ultimately leads to lesions in DNA, which 
should be repaired by DNA repair mechanisms, ought to reduce cancer risk. As a 
www.intechopen.com
 
DNA Repair and Human Health 
 
460 
consequence, a genetic change that alters the expression of the gene or the activity of the 
detoxifying protein produced may increase the amount of reactive carcinogen present, thus, 
increasing the risk of cancer development. As an example, CYP1A1 and CYP2D6 phase I 
enzymes, are induced by, and act on, carcinogens found in tobacco smoke. Additionally, 
CYP2E1, an enzyme that metabolizes ethanol, is also a candidate because epidemiological 
studies suggest that breast cancer risk is increased with alcohol consumption (Hasler, 1999). 
Environmental carcinogens interact with DNA as a result of complex metabolisms, 
involving phase I and phase II enzymes giving rise to several biomarkers of lesion. There are 
several specific biomarkers for evaluation of specific exposures. For instance, several 
environmental carcinogenic compounds (e.g. Aflatoxin B1, Benzo(a)Pyrene) react with DNA 
and/or proteins giving rise to specific adducts (Taioli et al., 2007; Wu et al., 2002).  However, 
apart from the specific biomarkers, exposure to these compounds leads to appearance of 
unspecific biomarkers as well (El-Zein et al., 2011). 
In spite of being usually unspecific biomarkers of lesion, there is evidence of correlation 
between increased frequency of chromosomal aberration (CA), micronuclei and cancer 
incidence in humans, which supports the use of cytogenetic human monitoring for cancer risk 
assessment (Bonassi et al., 2007; Bonassi et al., 2011; Dhillon et al., 2011). The levels of the 
different biomarkers studied are not directly correlated with the levels of exposure, suggesting 
that intra-individual susceptibility plays an important role. Several studies have shown that 
the level of biomarkers arising from environmental and/or occupational exposure may be 
modulated by polymorphic genes (Bonassi et al., 2011; Dhillon et al., 2011; Pavanello & 
Clonfero, 2000). As an example, experiments conducted in our laboratory concerning the 
evaluation of occupational exposure to Polycyclic Aromatic Hydrocarbons (PAHs), showed 
that the levels of aromatic DNA adducts are higher in smokers than in non smokers and the 
individual levels of DNA adducts in smokers is dependent on the CYP1A1 MspI 
polymorphism, located in the 3´ non-coding region of the gene, and that the presence of at 
least one allele with the restriction site leads to a significant higher level of DNA adducts when 
compared with the ones homozygous for the absence of this restriction site (Teixeira et al., 
2002). Interestingly the same CYP1A1 polymorphism has been associated with lung cancer risk 
among the Japanese and Caucasian populations (Kawajiri et al., 1990; Xu et al., 1996). The 
dependence of biomarkers' level with individual genotypes is also observed in human 
tumours. For instance, in lung cancer patients the level of DNA adducts has been correlated 
with CYP1A1 activity (Mollerup et al., 1999), and also with the GSTP polymorphisms (Rydberg 
et al., 1996). Thus, the parallel study of polymorphic genes associated with cancer 
susceptibility, and their correlation with biomarkers of exposure to carcinogens will improve 
our knowledge on the correlation between environmental exposure and individual variability. 
Additionally, these results prove the relevance of DNA repair pathways in cancer 
susceptibility, working as one important tool when other mechanisms fail.  
The data concerning the individual levels of biomarkers of exposure and the association 
between individual genetic polymorphisms and cancer risk suggest the involvement of 
environmental factors in some human cancers (e.g. carcinogen exposure) with individual 
risk factors (e.g. genetic polymorphisms).  Thus, the parallel study of polymorphic genes 
associated with cancer susceptibility, and their correlation with biomarkers of exposure will 
improve our knowledge on the correlation between environmental exposure and individual 
variability (Rueff et al., 2002) to different types of cancer namely in breast and thyroid 
cancers. 
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1.1 Breast cancer 
Breast cancer is the most common form of cancer among women, being responsible for  
the highest mortality rate from cancer among the female sex. However, the main causes 
related to this pathology remain unclear.  The risk of neoplasic disease has been connected 
with genetic and environmental factors. In fact, genes and the environment share the stage 
for most, if not all, common non-familial cancers, and are related to individual 
susceptibility.  
Several studies have identified two major susceptibility genes in breast cancer: BRCA1  
and BRCA2 (Hedenfalk et al., 2003; Narod & Foulkes, 2004). These genes have an important 
role in genome maintenance, in cell cycle control and in DNA repair, controlling 
homologous recombination repair (Scully & Puget, 2002; Venkitaraman, 2002). Analysis in 
families with high risk of breast cancer showed that individuals with point mutations in 
these genes have a 40-80% of probability to develop breast cancer. However, mutations in 
these two tumour-suppressor genes account for only 5-10% of all cases of breast cancer 
(Fackenthal & Olopade, 2007). 
Factors related to reproductive history and/or hormonal status have been found to confer 
increased risk (e.g., nulliparity, late age at first pregnancy, early menarche, late menopause), 
but the magnitude of the increased risk is generally not huge (less than 3) and the majority 
of breast cancer cases occur in women not demonstrably at high risk for this tumour. Recent 
evidence shows that there are other background genetic factors that contribute to the 
development of breast cancer, such as polymorphisms in DNA repair pathways that might 
increase cancer risk (Hunter et al., 2005; Silva et al., 2007). 
1.2 Thyroid cancer 
Thyroid cancer is the most frequent endocrine neoplasia, accounting for 1-5% of all cancers 
in women and 2% in men in most countries, being responsible for 0.32% of deaths related to 
malignant tumours. The incidence of this type of tumour has been responsible for 6.3% of 
total deaths promoted by endocrine tumours, which reflects its indolent nature. 
Nevertheless, 5-10% of all thyroid cancers are fatal (Inskip, 2001). 
The high frequency of cancer among family members of thyroid cancer patients supports 
the hypothesis that hereditary factors are important in the aetiology of this tumour. 
Among the sporadic cases of thyroid cancer the most common histological varieties are 
non-familial papillary and follicular thyroid carcinomas which shows a long-term (~10-
year) survival rate of more than 90%. These diseases are unusual in children and 
adolescents, and their incidence increases with age in adults, with the majority of cases 
occurring between 25 and 65 years of age. The papillary and follicular carcinomas are two 
to four times more frequent in women than in men, particularly during reproductive 
years, leading to the hypothesis that female hormones may be involved in the aetiology or 
pathogenesis of the disease (Grubbs et al., 2008). Exposure to ionizing radiation is the only 
verified cause of thyroid carcinogenesis in humans, especially when exposure occurs at a 
young age. However, individuals without previous exposure to ionizing radiation can 
also develop thyroid cancers, suggesting that other risk factors may also be involved in 
the aetiology of sporadic tumours. For example, dietary iodine deficiency has also been 
linked to this pathology. In fact, papillary tumours associated with radiation exposure 
usually have different forms of the activated RET proto-oncogene and at a higher 
frequency than that observed in spontaneous non-radiation induced tumours (Grubbs et 
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al., 2008; Sarasin et al., 1999), while follicular tumours are associated with somatic RAS 
gene mutations (Grubbs et al., 2008). Accordingly, the evidences suggested the existence 
of other risk factors for papillary and follicular tumours. Thus, the identification of 
susceptibility factors, both genetic and environmental, associated with individual 
predisposition to thyroid cancer could possibly give further insight into the aetiology of 
this malignancy.  
2. DNA repair pathways 
It is generally agreed that genetic polymorphisms are associated with, or are even the cause, 
of most common disorders with a genetic component like cancer. However, the complex 
metabolism of xenobiotic compounds involving different polymorphic genes could 
modulate the individual risk factor for cancer (Pavanello & Clonfero, 2000). 
DNA repair enzymes continuously monitor chromosomes to correct damaged nucleotide 
residues generated by exposure to carcinogens and cytotoxic compounds. The damage is 
partly a consequence of environmental agents such as ultraviolet (UV) light from the sun, 
inhaled cigarette smoke or deficient dietary habits. However, a large proportion of DNA 
alterations are caused unavoidably by endogenous mutagens, such as reactive oxygen 
species and metabolites that can act as alkylating agents. Genome instability caused by the 
great variety of DNA-damaging agents would be an overwhelming problem for cells  
and organisms.  Thus, DNA repair is a ubiquitous process throughout the living world  
and defective DNA repair is a risk factor for many types of cancer.  Its universality reflects 
the constant challenge to the integrity of any genome from the inherent instability of DNA, 
the natural limitations of the accuracy of DNA synthesis and the challenge of the 
environment.  
Recent evidence that some DNA repair functions are haploinsufficient adds weight to the 
notion that variants in DNA-repair genes constitute part of the spectrum of defects 
contributing to cancer risk. A coherent understanding of the genomics of human DNA 
repair genes, especially single nucleotide polymorphisms (SNPs), will greatly facilitate the 
investigation of the role that these variations play in modulating carcinogenesis. 
Several studies have shown that genes directly involved in DNA repair and in the 
maintenance of genome integrity, or genes indirectly involved in the repair of DNA damage 
through the regulation of the cell cycle, are critical for protecting against the mutations that 
lead to cancer (Hakem, 2008). Evidence suggests that the difference in DNA repair capacity 
among individuals is genetically determined, and that reduced DNA repair capacity 
constitutes a statistically significant risk factor for development of several cancers, 
associated with reduced protein function rather than absence of its function. Recently a 
number of polymorphisms of genes that encode for DNA repair proteins have been 
described (Wood et al., 2005). However, we will not discuss the mechanisms of these 
pathways in detail; instead we will focus on how epidemiologic studies contribute to 
understand the role of genetic polymorphisms present in DNA repair genes and individual 
susceptibility to breast and thyroid cancers.  
2.1 BER – Base excision repair  
The base excision repair (BER) pathway is mainly responsible for the lesion-specific removal 
that arises from endogenous or exogenous agents inducing base damage, which are the 
most frequent insult in cellular DNA. Reactive oxygen species (ROS) are produced from 
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endogenous sources, most notably the oxidative metabolism in the mitochondria, and from 
exogenous sources, such as ionizing radiation. ROS attack DNA readily, generating a variety 
of DNA lesions, such as strand breaks and oxidized bases. If not properly removed, DNA 
damage can be potentially devastating to normal cell physiology, leading to mutagenesis 
and/or cell death, especially in the case of cytotoxic lesions that block the progression of 
DNA/RNA polymerases (Maynard et al., 2009). BER pathway involves two sub-pathways, 
the short-patch responsible for the replacement of a single base, and the long-patch, which 
results in the incorporation of 2-13 nucleotides. The two pathways progress through 
different major processes that initially involve the removal of the damage base by 
glycosylases (Li et al., 2010).  
2.1.1 BER and breast cancer 
Several enzymes of the BER pathway act in concert to keep the DNA intact and maintain 
genomic integrity. One of the most studied genes of BER pathway has been the XRCC1 
gene. XRCC1 is a scaffolding protein that is involved in the repair of single-strand breaks, 
the most common lesion in cellular DNA (Li et al., 2009). Concerning the XRCC1 gene 
polymorphisms, several studies suggest a dual effect of these SNPs in cancer risk.  In fact, 
genetic variation in six BER pathway genes (XRCC1, ADPRT, APEX1, OGG1, LIG3, and 
MUTYH) is associated with breast cancer risk in two large population-based case-control 
studies in the United States and Poland (Zhang et al., 2006). Additionally, XRCC1 
haplotypes revealed no significant association between Trp194-Arg399 haplotype and risk 
of breast cancer, neither in Western nor Asian countries, but a recent meta-analysis has 
indicated that the Arg194-Gln399 haplotype of XRCC1 might be a risk factor for breast 
cancer in Asian countries (Saadat, 2010). However, other meta-analysis suggests that 
polymorphisms Arg280His and Arg399Gln may modify breast cancer risk differently in 
Caucasian and Asian populations (Li et al., 2009), and a meta-analysis study between the 
breast cancer and the XRCC1 polymorphisms Arg194Trp, Arg399Gln  and Arg280His in 
different inheritance models suggested that Arg399Gln was associated with a trend of 
increased breast cancer risk when using both dominant and recessive models to analyze the 
data (Huang et al., 2009). 
Results published by our group concerning the breast cancer risk and XRCC1 Arg194Trp 
and Arg399Gln polymorphisms do not show any association between these polymorphisms 
and breast cancer risk, but it was observed that menopausal age together with XRCC1 
Arg194Trp and Arg399Gln polymorphisms might be involved in individual susceptibility 
towards breast cancer (Silva et al., 2007) 
DNA polymerase beta (Polβ) provides most of the gap-filling synthesis at abasic sites of 
damaged DNA in the base excision repair pathway, a polymorphic key gene in BER. A case-
control study has shown two polymorphisms in the Polβ protein, the Pro242Arg and 
Lys289Met, associated with breast cancer risk and cancer progression. In fact, a strong 
association between breast cancer occurrence and the TT genotype of the Lys289Met (C to G 
transition) polymorphism and the CG genotype of the Pro242Arg polymorphism was found. 
Polymorphism-polymorphism interaction between the TT genotype of the Lys289Met and 
the CG genotype of the Pro242Arg (C to G transition) polymorphisms increased the risk of 
breast cancer (Sliwinski et al., 2007) 
Several DNA BER repair gene polymorphisms have been described, which affect DNA 
repair capacity and modulate cancer susceptibility, namely with the risk of acute skin 
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reactions following radiotherapy. In fact, it was reported that XRCC1 399Gln or APEX1 
148Glu alleles may be protective against acute skin reactions following radiotherapy 
(Chang-Claude et al., 2005). However, it was not confirmed in breast cancer patients 
(Bartsch et al., 2007). In addition, in a retrospectively evaluation of SNPs in DNA repair 
genes, it was observed that XRCC1 Arg399Gln may be predictive of survival outcome in 
patients with metastasis breast cancer treated with DNA damaging chemotherapy (Bewick 
et al., 2006). Outcome and survival in anthracycline-based and cyclophosphamide/ 
methotrexate/5-fluorouracil-based chemotherapy of invasive breast cancer are 
unpredictable. It was observed that, carriers of the XRCC1 1196 AA genotype had a reduced 
risk for recurrence/death and patients treated with chemotherapy but not radiotherapy, 
suggesting that DNA repair enzyme XRCC1 is a potential treatment predictor for the 
outcome and survival of anthracycline and cyclophosphamide/methotrexate/5-
fluorouracil-based chemotherapy of invasive breast cancer (Jaremko et al., 2007). However, 
among incoherent results, recent studies strongly suggest a main role of BER in 
chemotherapy (Bewick et al., 2006; Goode et al., 2002b; Kelley & Fishel, 2008) in breast 
cancer. 
2.1.2 BER and thyroid cancer 
The results obtained by our group, do not reveal a significant involvement of XRCC1 
Arg194Trp and Arg399Gln, OGG1 Ser326Cys, APEX1 Asp148Glu, MUTYH Gln335His and 
PARP1 Val762Ala polymorphisms on the individual susceptibility towards thyroid cancer, 
since the frequency of the different genotypes are similar in control and cancer patients 
population (data not published).  
Additionally, since thyroid cancer incidence is recurrently reported to be higher in women 
(which was also the predominant gender in our case group), we compared genotypic 
frequencies according to sex among thyroid cancer patients (in order to examine for any sex-
specific genetic effect), but the frequency of the different genotypes considered did not differ 
significantly with gender in thyroid cancer patients (data not published).  
Concerning the role of XRCC1 polymorphisms in thyroid cancer, a study reported by (Ho et 
al., 2009) showed, in white non-Hispanics, that XRCC1 194Trp variant allele may be 
associated with increased risk of differential thyroid carcinoma (DTC), while the XRCC1 
399Gln variant allele may be associated with decreased risk of DTC. These results are in 
agreement with the data reported by (Chiang et al., 2008) in Chinese DTC populations. 
However, Sigurdson and colleagues (Sigurdson et al., 2009) reported that, among residents 
near Semipalatinsk, Kazakhstan XRCC1 Arg194Trp is associated with decreased thyroid 
nodule risks for increasing minor alleles, and a similar patterns of association were observed 
for a small number of papillary thyroid cancers.  The results in our study do not reveal an 
association between XRCC1 Arg194Trp genotypes and thyroid cancer risk, and these 
differences might be due a different risk factors for thyroid tumours (exposure to ionizing 
radiation (Sigurdson et al., 2009) versus sporadic tumours), and genetic background of 
different populations.    
Concerning XRCC1 Arg280His polymorphism only a positive association was described in 
Caucasian populations (Garcia-Quispes et al., 2011). Interestingly, in white non-Hispanics, 
the XRCC1 399Gln variant allele may be associated with decreased risk of DTC, and in 
Caucasians,  who lived in the areas of the Russian Federation and Belarus contaminated 
with radionuclides from Chernobyl fallout, it was observed that the XRCC1 Arg399Gln 
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polymorphism, regardless of radiation exposure, was associated with a decreased risk of 
Papillary Thyroid Carcinoma (PTC) according to the multiplicative and dominant models of 
inheritance (Sigurdson et al., 2009). However, we cannot exclude that other XRCC1 gene 
polymorphisms may interact, alone or when combined, with other genes such as the ADPRT 
(Chiang et al., 2008). However, our results do not support an association between thyroid 
cancer risk and the XRCC1 Arg399Gln polymorphism, suggesting the need of larger studies 
and/or a meta-analysis, in order to understand the role of the XRCC1 polymorphisms in 
thyroid cancer.  Additionally, we can rule out the utility of XRCC1 haplotypes in predicting 
DTC risk.  
In general, the results reviewed suggest that larger studies are required to define the role of 
XRCC1 polymorphisms in susceptibility to well differentiated thyroid cancer. However, the 
scarcity of data concerning other BER genes creates a gap in knowledge about the effective 
role of polymorphisms in BER pathway and individual susceptibility to thyroid cancer.   
2.2 NER – Nucleotide excision repair 
Several DNA repair pathways have evolved to repair DNA adducts and function to prevent 
genomic instability and promote cell survival. The nucleotide excision repair (NER) 
pathway is important for DNA repair, removing adducts responsible for the distortion of 
double helix. Such adducts can be caused by UV irradiation and environmental agents such 
as tobacco smoke (polycyclic aromatic hydrocarbons). This pathway is also the main 
mechanism for the repair of bulky DNA adducts generated by breast cancer 
chemotherapeutic agents, such as platinum drugs and cyclophosphamide and may be 
involved in the repair of nonbulky DNA lesions that result from oxidative damage (Bewick 
et al., 2011; Oksenych & Coin, 2010). Failure to eliminate these lesions can lead to 
oncogenesis, developmental abnormalities and accelerated ageing.  
NER pathway involves several proteins that act in order to restore the normal homeostasis 
of the cell. There are two sub-pathways of the NER pathway, global-genomic-NER (GG-
NER) and transcription-coupled NER (TC-NER), which differ only in the step involving 
recognition of the DNA lesion (Shuck et al., 2008). The complex XPC-HR23B or CSA and 
CSB proteins are responsible for the initial step in the GG-NER and in TC-NER, respectively. 
The recognition of the distortion of double helix is followed by the opening of the DNA by 
the XPB and XPD ATPases/helicases of the transcription/repair factor (TFIIH). TFIIH is a 
multisubunit factor composed of 10 subunits which catalyses helix opening during NER (Li 
et al., 2010). The DNA strand opening favors the recruitment of XPA and RPA, which help 
to enlarge the opened structure and drive the dissociation of the CDK activating kinase 
(CAK) complex from TFIIH. The recruitment of the endonucleases XPG and XPF triggers 
dual incision and excision of the protein-free damaged oligonucleotide. The gap is filled by 
the resynthesis machinery and the DNA extremities sealed (Oksenych & Coin, 2010).  
Deficiency in NER results in three rare genetic disorders: Xeroderma pigmentosum (XP), 
trichothiodystrophy (TTD) and Cockayne syndrome (CS), characterize by increased cancer 
frequencies, neurodegeneration and ageing.  
2.2.1 Nucleotide excision repair and breast cancer 
Genomic instability is a hallmark of all cancers (Hanahan & Weinberg, 2000). At the cellular 
level, damaged DNA that is not properly repaired can lead to genomic instability, apoptosis, 
or senescence, which can greatly affect the organism’s development and ageing process 
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(Hakem, 2008). DNA repair pathways are among the mechanisms most frequently 
deregulated in cancer. These mechanisms allow non-transformed cells to repair their DNA 
after specific damage or in some circumstance, to induce apoptosis if repair is not possible. 
This mechanism protects against uncontrolled proliferation in the context of abnormal 
genetic background. Disruption of these pathways in cancer produces an increase in 
chromosome breaks and mutagenesis (Amir et al., 2010). 
Several polymorphisms in NER genes have been described. However, studies investigating 
the association of NER genes polymorphisms with breast cancer risk produced controversial 
results.  
Genetic polymorphisms identified in genes encoding DNA repair enzymes are believed to 
be candidates for associations with several types of cancers, including breast cancer. One of 
the most studied NER genes is ERCC2 (XPD), which plays a key role in NER pathway. 
Several polymorphisms in the ERCC2 gene have been described, including the commonly 
occurring Asp312Asn and Lys751Gln. However, the published results have been 
contradictory. Recently, one meta-analysis study revealed no association between both 
polymorphisms and breast cancer risk (Pabalan et al., 2010). We had also reported similar 
results previously (Silva et al., 2006a). The main causes for breast cancer remain unclear; 
however some environmental compounds have been regarded as increasing the risk of 
breast cancer, especially the ones responsible for generation of DNA adducts (PAHs, 
aromatic amines). The ERCC2 polymorphisms have been extensively correlated with high 
levels of DNA adducts (or lower DNA repair capacity). This reduction in DNA repair 
capacity is also influenced by these polymorphic variations, being predictive of DNA repair 
capacity (Crew et al., 2007; Shi et al., 2004).  
Other genes of NER pathway have been studied, though not so often, in association studies. 
For example, the gene ERCC4 (XPF) that codes for the subunit of the protein complex 
ERCC1-ERCC4 responsible for the removal of the damaged single-stranded fragment (Lee et 
al., 2005), have been studied and the results revealed a significant association of Arg415Gln 
polymorphism and breast cancer risk (Smith et al., 2003), but not for Ser835Ser 
polymorphism as described by Lee and colleagues. This research team showed a combined 
effect between the ERCC4 synonymous polymorphism and Asp312Asn ERCC2 
polymorphism (Lee et al., 2005). The other sub-unit of protein complex ERCC1-ERCC4, 
coded by ERCC1 gene, has also been a target of some epidemiologic studies (Bewick et al., 
2011; Crew et al., 2007; Lee et al., 2005; Shin et al., 2008), resulting in contradictory data.  
XPG (ERCC5) gene is also required for the removal of the damaged single-stranded nucleotide 
fragment, together with the complex ERCC1-ERCC4. Rajaraman and colleagues described in 
their work the relevance of one polymorphism of ERCC5 gene providing suggestive evidence 
that variant allele of Asp1104His was associated with increased risk of breast cancer overall, 
and suggesting further an increased susceptibility to breast cancer in radiologic technologists 
exposed to low levels of radiation (Rajaraman et al., 2008). However, there is no agreement 
regarding the role of this gene in breast cancer susceptibility (Crew et al., 2007; Jorgensen et al., 
2007; Kumar et al., 2003; Mechanic et al., 2006; Shen et al., 2006). 
XPC encodes a basic protein that is essential for damage recognition in sub-pathway GG-
NER (Sugasawa, 2008). Several studies have been developed concerning the role of XPC 
gene polymorphisms in breast cancer risk. However, the results have been inconsistent. 
Early this year a meta-analysis including 11 studies was published revealing no associations 
between the polymorphisms of XPC gene under study and breast cancer risk (Zheng et al., 
2011). However, the role of this gene in breast cancer should not be excluded, since it was 
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shown that XPC gene, as other XP gene products, interact with and stimulate specific DNA 
glycosylases (e.g. thymine DNA glycosylase (TDG)), initiators of BER, beyond their 
functions in NER pathway (Sugasawa, 2008). Moreover, gene–gene and gene–environment 
interactions should also be considered which are not in the meta-analysis studies. 
XPA protein interacts with many of the core repair factors in NER pathway, and without it, 
no stable pre-incision complex can form, nor can NER occur, making it the limiting factor in 
damage recognition (Shuck et al., 2008). However, XPA gene has not been extensively 
studied in connection with breast cancer risk (Crew et al., 2007; Jelonek et al., 2010; Shen et 
al., 2006), and the results published did not described this gene as potentially related with 
breast cancer risk.  
Many more polymorphisms in the NER genes have been found, however there aren’t 
enough consistent epidemiologic studies into the link between this pathway and breast 
cancer. More studies are needed to form any reliable conclusions. 
The new era in cancer treatment and prevention lies in the ability to treat patients individually 
according to their genetic constitution and the DNA repair status of their tumours. The nature 
of DNA lesions caused by therapeutic agents requires complex repair mechanisms, possibly 
involving simultaneously different repair pathways. DNA damage acquired from these 
treatments can initiate a number of cellular pathways involved in DNA repair, cell cycle 
control, metabolism and apoptosis (Bewick et al., 2011). For example, it is well known the 
importance of NER pathway in repair of bulky DNA adducts, such those caused by tobacco 
smoke as well as intrastrand cross-links (ICL) caused by chemotherapeutic agents, such as cis-
platinum or anthracyclines (Latimer et al., 2010; Saffi et al., 2010). If so, SNPs in genes in this 
pathway may significantly affect DNA repair efficiency, influencing clinical outcome and thus 
may help identify patients that can benefit from certain treatments.  
2.2.2 Nucleotide excision repair and thyroid cancer 
The main, and well documented, cause for thyroid cancer is ionizing radiation, although 
other risk factors have been pointed out as candidates, such as dietary iodine deficiency, 
hormonal factors, lymphocytic thyroiditis and familial history (Kondo et al., 2006).  
In a previous report, we found a significant association between a haplotype of two SNPs 
(Asp312Asn and Lys751Gln) in ERCC2 gene, and thyroid cancer risk (Silva et al., 2005) 
suggesting that this pathway may be relevant for thyroid carcinogenesis. Later we also 
conducted another study including more SNPs in different genes of NER (CCNH Val270Ala, 
CDK7 Asn33Asn, RAD23B Ala249Val, ERCC1 Gln504Lys, ERCC4 Arg415Gln, ERCC5 
Asp1104His, ERCC5 Cys526Ser, ERCC6 Arg1230Pro, ERCC6 Gln1413Arg, XPC Ala499Val and 
XPC Lys939Gln) on the individual susceptibility to non-familial thyroid cancer (manuscript in 
preparation), where we showed that patients carrying at least one variant allele of CCNH 
Val270Ala polymorphism seems to be at increased risk for thyroid cancer. To our knowledge, 
no other reports have been published trying to find susceptibility alleles in NER genes 
associating them with risk for thyroid cancer. One possible explanation for this is that the 
lesions produced by ionizing radiation are more likely to be repaired by BER, NHEJ and HR.  
Several authors have described the increased incidence of a second malignancy in patients 
after diagnosis of thyroid cancer (Brown et al., 2008; Canchola et al., 2006; Garner et al., 2007; 
Verkooijen et al., 2006), pointing out breast cancer as the most frequent occurrence. 
However, some authors also considered the opposite, thyroid cancer being subsequent to 
breast cancer, suggesting the exposure to radiotherapy as the main cause of second 
malignancy in adjacent organs as a result of scattered radiation (Adjadj et al., 2003; Huang et 
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al., 2009). Furthermore, the incidence of other tumours might not represent a therapy effect 
but rather might be due to common risk factors. Therefore, the exposure to ionizing 
radiation and hormonal factors has been the risk factors well documented for both 
malignancies, although, there is no consensus in the results.   
2.3 MMR – Mismatch repair 
The Mismatch Repair (MMR) pathway plays a crucial role in repairing mismatches, which 
are small bulges in the DNA duplex, caused by small insertions, deletions or nucleotide 
substitutions in one strand of the duplex. Mismatches can be generated during DNA 
replication and repair. The failure of MMR leads to high mutation rates, microsatellite 
instability (MSI), losses of heterozygosity (LOH), reduction in apoptosis processes and 
increases in cell survival, as well as predisposition for carcinogenesis (Schofield & Hsieh, 
2003; Schroering et al., 2007). MMR is also associated with an anti-recombination function, 
suppressing homologous recombination and plays a role in DNA-damage signaling (Smith 
et al., 2008). 
The main MMR pathway is initiated by the recognition of a mismatch by the heterodimer 
consisting of the MSH2 and MSH6 proteins (also called MutSǂ). MutSǂ is responsible for the 
recognition of base mismatches and insertion/deletion loop (IDLs) in mono- to 
tetranucleotide repeats. This complex, MutSǂ, is able to recognize most base-base 
mismatches and short IDLs (Hsieh & Yamane, 2008). 
Another MMR pathway, consisting of MSH2 and MSH3 heterodimers (MutSǃ) is primarily 
responsible for binding to and correcting insertion/deletion mutations, preferentially 
dinucleotide and larger IDLs. Upon DNA mismatch recognition the repair process proceeds 
with the participation of the heterodimer consisting of MLH1 and PMS2 (also called 
MutLǂ), which acts as an endonuclease. Subsequent DNA excision, directed by strand 
breaks located either 5' or 3' to the mispair, is carried out by the exonuclease EXO1 (Hsieh & 
Yamane, 2008; Jiricny, 2006).   
2.3.1 Mismatch repair and breast cancer 
The MSH2 gene is central in mismatch recognition and has been the most studied gene of 
MMR. There are several studies reporting mutations  (Murata et al., 2002) and polymorphisms 
in several MSH2 variants (Poplawski et al., 2005; Wong et al., 2008). Poplawski and colleagues 
showed a significant association between Gly322Asp polymorphism of the MSH2 gene and 
breast cancer risk (Poplawski et al., 2005). However, another study of several families 
conducted by Wong and colleagues did not find any association between MSH2 and breast 
cancer (Wong et al., 2008).  However, the scarcity of data about the involvement of 
polymorphisms in other MMR genes in breast cancer susceptibility, contributed to our MMR 
multigene study, which included MSH3, MSH4, MSH6, MLH1, MLH3, PMS1 and MUTYH 
genes (Conde et al., 2009). Our results showed the potential involvement of Leu844Pro MLH3 
gene polymorphism in breast cancer susceptibility, as well as some SNP-SNP interactions. 
Different activities and functions of these genes as well as SNP variations may alter the level of 
repair, leading to higher rates of mutations and therefore an increase of breast cancer risk or 
conversely play a protective role in breast carcinogenesis.  
2.3.2 Mismatch repair and thyroid cancer 
To our knowledge, there are no data reporting the involvement of mismatch repair genes in 
thyroid cancer susceptibility. 
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2.4 DSB - Double strand breaks repair  
Double-stranded breaks (DSBs) are the most injurious DNA damage. The failure to repair 
DSBs can result in chromosomal abnormalities, such as DNA translocations, that lead to 
cancerigenesis and are common in many cancers. DSBs can occur as a consequence of direct 
exposure to harmful exogenous agents, such as ionizing radiation, or by endogenous by-
products of many metabolic processes, such as reactive oxygen species (ROS). They can also 
be generated during V(D)J recombination and when DNA single-strand breaks are 
encountered during DNA replication. The termini of chromosomes can also be recognized 
as DSB due to defective metabolism of telomeres. In order to face the threat of DSBs, 
prokaryotes and eukaryotes developed two mechanisms of repair, DNA end-joining and 
homologous repair. 
DNA end-joining is the most straightforward repair mechanisms of DSBs, since it simply 
rejoins the broken ends regardless of the genetic consequences. There are two processes 
through which DNA end-joining can occur, non-homologous end-joining (NHEJ) and 
microhomology mediated end-joining (MMEJ). The first one is a Ku-dependent mechanism 
while the second one is Ku-independent. Both processes can maintain structural integrity, 
although, do not guarantee genetic integrity, being both error-prone and capable of 
generating new mutations. In NHEJ pathway, DNA ends are recognized and targeted by a 
heterodimeric Ku70/80 complex leaving the broken ends accessible for other factors. This 
DNA binding complex is important for recruitment of additional NHEJ proteins. Once 
bound to DNA, Ku proteins recruit the large DNA-dependent protein kinase catalytic 
subunit (DNAPKcs). The association of DNAPKcs-DNA-Ku complex activates the 
serine/threonine kinase activity of DNAPKcs contributing to the phosphorylation of the 
histone H2AX at lesion site and other factors such as nucleases. In case of incompatible ends, 
broken ends are processed by an endonuclease protein, named Artemis, trimming DNA 
overhangs and hairpins formed at the transition of double to single stranded DNA. 
Alternatively, the ssDNA tails can be filled in by polymerases (polµ and polλ). NHEJ repair 
is finalized by the complex XRCC4/LigaseIV that rejoins DNA ends. When broken DNA 
ends are not accessible for Ku proteins, due to other polypeptides covalently attached to 
DNA ends, the end joining occurs via Ku-independent pathway (MMEJ). The foremost 
distinguishing property of MMEJ is the use of 5–25 nucleotides sequences during the 
alignment of broken ends before joining, thereby resulting in larger deletions flanking the 
original break (Lieber, 2010; McVey & Lee, 2008). 
In S-phase of cell cycle, there is a second copy of the genome, thus repair machinery can use 
this sister chromatid as template in order to achieve an error-free repair. This mechanism is 
known as homologous recombination repair (HR). In human cells, the early events are not 
completely understood, however the recruitment of the Mre11-Rad50-Nbs1 (MRN) complex 
and the phosphorylation of histone H2AX are two probable events, although these are not 
specific to HR since they can also occur, to a lesser extent, in NHEJ and MMEJ. Unlike end-
joining repair, HR requires extensively resected broken ends to generate a 3’ single-stranded 
(ss) DNA tail. Firstly, MRN complex exposes both 3’ ends, the 3’ ssDNA tail is then 
stabilized by binding of RPA which facilitates the assembly of RAD51. With the help of 
RAD52 and BRCA2, a nucleoprotein filament is formed along the ssDNA tail and the search 
for homology in the sister chromatid by RAD51 is initiated. RAD51 catalyzes strand 
exchange during which ssDNA invades homologous duplex DNA forming a Holliday 
junction, which provides a primer to initiate new DNA synthesis, and a displacement loop 
(D-loop). Once the D-loop is formed, cells may undergo a process termed synthesis-
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dependent strand annealing. The 3’ end in the D-loop is extended by repair synthesis and 
then the newly synthesized DNA strand dissociates to anneal to its original second strand to 
complete the reaction (Li & Heyer, 2008). 
2.4.1  DSB and breast cancer 
Linkage analysis of families with a high risk of breast cancer has identified two major 
susceptibility genes, BRCA1 and BRCA2. The BRCA1 and BRCA2 genes are numerically the 
most important susceptibility genes for breast cancer, accounting for more than 80% of 
incidence in families with six or more cases of early-onset breast cancer. BRCA1 tumours are 
typically invasive ductal carcinomas in which there is a high incidence of triple negative 
phenotype (negative for estrogen receptor, progesterone receptor and HER2). On the 
contrary, no distinctive histopathological phenotype has been described in BRCA2 tumours. 
The main roles of the BRCA1 and BRCA2 are well known and are reviewed elsewhere 
(Gudmundsdottir & Ashworth, 2006). 
Hereditary breast cancer only accounts for 5-10% of all cases (Dapic et al., 2005). Although 
high penetrance genes, such as BRCA1 and BRCA2, can explain some of these cases, the 
sporadic cases are still not well understood and the search for susceptibility genes continues. 
The fact that two major hereditary breast cancer genes are involved in DSB repair pathway, 
point to the relevance of DSBs in sporadic breast cancer risk. Thus, due to the emergence of 
comprehensive high density maps of SNPs and affordable genotyping platforms, several 
genes involved in DSB repair have been genotyped in breast cancer patients, in order to 
found susceptibility alleles. The most studied genes are NBS1, RAD51, XRCC2, XRCC3, 
BRCA1 and BRCA2. To a lesser extent, the NHEJ genes are also studied. 
The NBS1 gene codes for the protein NBS1 that participates in the MRN complex 
responsible for the DSB recognition and the early stages of the repair, as described above 
(Stracker & Petrini, 2011). Therefore, many studies were conducted in order to verify if a 
variant of this gene could be a susceptibility allele for breast cancer (Goode et al., 2002a; 
Kuschel et al., 2002; Lu et al., 2006; Millikan et al., 2005; Pooley et al., 2008; Silva et al., 2010; 
Smith et al., 2008; Zhang et al., 2005). The most studied SNPs were Asp399Asp, Glu185Gln, 
Leu34Leu and Pro672Pro. With the exception of Glu185Gln, all variants are synonymous, 
thus do not alter the conformational structure of the protein. No correlation was found 
between these polymorphisms and breast cancer. With the exception of a couple of studies 
(Lu et al., 2006; Smith et al., 2008), all results from studies in different populations regarding 
Glu185Gln were negative. Lu et al. found statistically significant association of the SNPs 
Glu185Gln and 5’ UTR 924T>C individually and haplotypes in young non-Hispanic white 
women in Texas, USA (Lu et al., 2006). Smith et al. showed that there were significant trends 
in breast cancer risk with increasing numbers of risk genotypes (at least one variant allele) of 
NBS1 185 GluGln/GlnGln in African-Americans (Smith et al., 2008). These discrepancies 
across studies might be associated with different genetic backgrounds, different risk factors 
in different populations, and the sample size of these studies. Thus, more studies are 
required in order to make any statement, although, according to the results obtained until 
now, NBS1 is not a probable low penetrance gene. 
The RAD51 protein is responsible for the central activity of the HRR pathway, in which it 
catalyses the invasion of the broken ends of the DSB into the intact sister chromatid. Among 
several polymorphisms in RAD51 gene, a functional SNP at position 135 in 5’ UTR, 
changing a guanine to cytosine, was reported. Indeed, it was stated that this variant allele 
improves RAD51 expression (Hasselbach et al., 2005). Consequently, many molecular 
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epidemiological studies were performed with the purpose of examining an association 
between this RAD51 variant and susceptibility to breast cancer. Many inconsistencies were 
found, even within the same population. Thus, a meta-analysis of all results found until now 
might bring some more precise estimation of the association of this SNP with susceptibility 
to breast cancer. Recently, four important meta-analyses (Gao et al., 2011; Sun et al., 2011; 
Wang et al., 2010; Zhou et al., 2011), covering tens of other studies and thousands of 
subjects, were unanimous to state that the variant allele of RAD51 G135C may contribute to 
increased breast cancer susceptibility, which is in accordance with biological function study, 
which showed a more aggressive and poor prognosis phenotype (Costa et al., 2008). Zhou et 
al. also reported that the C variant of this SNP is associated with an augmented breast 
cancer risk among the BRCA2 mutation carriers, but not BRCA1 (Zhou et al., 2011). 
Therefore, taking into account these meta-analyses, RAD51 G135C is a good candidate for a 
low penetrant risk factor for breast cancer. Recently, however, Yu et al. stated that these 
studies are not convincing since most are biased. According to the authors the populations 
have no representation of real general breast cancer cases since they took into account all 
breast cancer cases, including the BRCA1 and BRCA2 mutation carriers (Yu et al., 2011). The 
authors suggest that correct experimental design should be followed, such as subgroup 
meta-analysis in specific populations.  
XRCC2 protein is a RAD51-related protein, essential for efficient HRR, and hence for 
maintenance of chromosome stability, making part of the nucleoprotein filament that acts as 
a cofactor for the RAD51 strand invasion and exchange activities, although there are other 
indications of its involvement in the late stages of the HRR pathway, namely the branch 
migration and Holliday junction resolution (Dudas & Chovanec, 2004). The XRCC2 
Arg188His polymorphism is by far the most studied in this gene. Many are in disagreement 
and contradictory, thus, recently, a meta-analysis was published by Yu et al. were all results 
published until then were analyzed and a more convincing and precise estimation of the 
association of this SNP and breast cancer was made (Yu et al., 2010). The authors reached 
the conclusion that XRCC2 Arg188His is not associated with individual susceptibility for 
breast cancer. However, they suggested that this SNP can modify the risk for breast cancer 
in response to exogenous compounds, and stressed the importance of investigating this 
possibility. Subsequent to this publication, a report made by us (Silva et al., 2010) was 
published with results concerning this SNP in a Portuguese population. The results were 
also negative when the SNP alone was considered, although, when the population was 
stratified according to the breast feeding status, it was observed that individuals that never 
breast fed and carried one variant allele of this polymorphism have a decreased risk for 
breast cancer. It is known that women that breast fed for long periods have a reduced risk 
for breast cancer. This can be explained by the fact that the exfoliation of ductal cells as a 
consequence of breast feeding might remove a significant number of cells with genetic 
damage, preventing their transformation into neoplastic cells. In those women that do not 
breast fed we have found a protective role of the variant allele of XRCC2 Arg188His that 
might be related to a more efficient repair of DNA lesions. However, taking into 
consideration the size of our sample stratification, the small number of cases could act as a 
limitation factor. Thus, to exclude false positive results, further investigation in larger 
populations needs to be done. 
XRCC3 protein is also a Rad51-related protein that participates in homologous 
recombination repair to maintain chromosome stability. XRCC3 forms filamentous 
structures in complex with Rad51C that assists RAD51-mediated strand invasion (Li & 
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Heyer, 2008). XRCC3 is a highly polymorphic gene and many SNPs have been already 
described. Among them, XRCC3 Thr241Met, 5’UTR A/G and IVS5-14 A/G are the most 
studied. As a result of inconclusive data of the several studies reported, four meta-analyses 
were published, three covering XRCC3 Thr241Met (Economopoulos & Sergentanis, 2010; 
Garcia-Closas et al., 2006; Lee et al., 2007) and two the XRCC3 5’UTR A/G and IVS5-14 A/G 
(Garcia-Closas et al., 2006; Qiu et al., 2010a). In a first approach to obtain accurate results 
García-Closas et al. performed a meta-analysis with two populations, one from USA and 
other from Poland (Garcia-Closas et al., 2006). The authors concluded that the variant allele 
of these SNPs has a weak association with breast cancer. Later Lee et al. conducted a case-
control with a Korean population and a meta-analysis of other 12 studies (Lee et al., 2007). 
The results fail to show statistically significant association of XRCC3 Thr241Met with breast 
cancer. However the meta-analysis suggests a weak association between XRCC3 Thr241Met 
and breast cancer, highlighting the differences between oriental and occidental populations. 
Recently, two more meta-analysis were published (Economopoulos & Sergentanis, 2010; Qiu 
et al., 2010a). Economopoulos & Sergentanis performed a meta-analysis concerning XRCC3 
Thr241Met and the results seems to be similar to those reported previously, thus, variant 
allele is associated with elevated breast cancer risk in non-Chinese subjects (Economopoulos 
& Sergentanis, 2010). Indeed, the authors have some reservations with regards to the studies 
with Chinese populations since no consistent data were obtained. Qiu et al., in order to fill a 
shortage of meta-analysis of XRCC3 5’UTR A/G and IVS5-14 A/G, published a report 
encompassing all eligible data from several studies concerning these two SNPs (Qiu et al., 
2010a). The results suggest that the variant allele of XRCC3 5’UTR A/G is associated with 
breast cancer risk while the variant allele of XRCC3 IVS5-14 A/G has a protective effect on 
breast cancer. Subsequently to these reports a work conducted by us (Silva et al., 2010) 
showed that XRCC3 Thr241Met alone does not confer susceptibility to breast cancer. 
However, after stratification according to menopausal status, post-menopausal women 
carrying at least one variant allele seem to have lower risk for breast cancer, although 
stratifications applied to small populations could act as a limitation factor. 
Along with BRCA2, BRCA1 is well documented as a hereditary breast cancer susceptibility 
gene. However, there are much fewer published data addressing susceptibility alleles of 
BRCA1 in sporadic breast cancer (Cox et al., 2005; Freedman et al., 2005; Goode et al., 2002a; 
Huo et al., 2009). Of the four eligible reports, none showed association of common SNPs in 
BRCA1 with breast cancer susceptibility. One report described a haplotype in BRCA1 gene 
that may cause an increased risk for breast cancer, precisely, a 20% increment in risk for 
breast cancerigenesis. However, the authors failed to find out which variant is responsible 
for the association (Cox et al., 2005). Other study showed a possible association between an 
interaction of BRCA1 and ZNF350 with individual susceptibility for breast cancer (Huo et 
al., 2009). Similarly, BRCA2 has few studies what concern sporadic breast cancer. However, 
a meta-analysis of about 44,903 subjects was recently published about BRCA2 Asn372His 
polymorphism (Qiu et al., 2010b). This SNP is the most studied in this gene and according to 
the authors the variant allele may be a low-penetrant risk factor for breast cancer disease. 
However, the authors suggest that larger studies need to be done and homogeneous 
populations should be recruited, including well matched controls. Other meta-analysis also 
has reported the same results some years earlier (Garcia-Closas et al., 2006).Other study 
published by Ishitobi et al. reported null results for BRCA2 Asn372His but not BRCA2 
Met784Val in a Japanese population. Specifically, the BRCA2 Met784Val variant allele 
showed a significantly lower survival rate of 63% (Ishitobi et al., 2003). 
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To a lesser extent NHEJ genes were also studied. An early study found that the combined 
effect of individual SNPs of NHEJ genes may be significantly associated with breast cancer 
risk; indeed Fu et al. founded interesting results concerning estrogen exposure (Fu et al., 
2003). The authors stated that women with greater putative high-risk genotypes have an 
increased risk for breast cancer disease and the results were even more significant and the 
risk stronger in women that never had a history of pregnancy. The authors also found 
statistically significant results for Ku70 c.-1310 C>G and XRCC4 Thr1394Gly individually. 
Later, Willems et al. also found similar results for the Ku70 c.-1310 C>G SNP in a Belgian 
population (Willems et al., 2009). García-Closas et al. published a meta-analysis stating 
negative results for LIG4 Asp568Asp, Thr9Ile and XRCC4 IVS7-1A>G. Larger studies must 
be performed in order to verify these results and other populations should be taken into 
account (Garcia-Closas et al., 2006). 
2.4.2 DSB and thyroid cancer 
The only observed risk factor for thyroid cancer is ionizing radiation. However, most of 
cases do not have a history of ionizing radiation exposure and people exposed to X- or Ǆ-
rays, for example, not necessarily develop thyroid cancer. Thus, it is suggested that there 
might be an individual sensitivity to ionizing radiation due to genetic factors, such as 
polymorphic genes. Since ionizing radiation causes DSBs, is plausible to study SNPs in 
genes that are involved in the DSBs repair. Until now, few studies have been done 
concerning end-joining and homologous recombination repair. A study conducted by Bastos 
et al. observed that the coexistence of three or more variant alleles of XRCC3 Thr241Met and 
RAD51 5’UTR (Ex1-59G>T) genes were associated with a significant higher risk for thyroid 
cancer (Bastos et al., 2009). However, independently the SNPs show no association with 
thyroid cancer. This SNP-SNP association might lead to a deficit in the formation of the DNA 
damage–induced RAD51 foci and consequently a deficient repair by HRR system. Sturgis et al. 
also reported a possible association of the variant allele of XRCC3 Thr241Met with thyroid 
cancer (Sturgis et al., 2005). Indeed, among 10 SNPs studied, which include other SNPs of 
DSBs repair genes, such as BRCA1, BRCA2, RAD51, XRCC3 and XRCC7, only the XRCC3 
Thr241Met seems to confer susceptibility for thyroid cancer. Further molecular 
epidemiological and functional studies must be performed in order to assure the accuracy of 
the results reported by both groups. Other study conducted by Gomes et al. shows a marginal 
association of NHEJ pathway SNPs with thyroid cancer (Gomes et al., 2010). To be precise, 
statically significant results were found for association of Ku80 3’UTR Ex21-238G>A and 
Ex21+338T>C SNPs with papillary tumours, after stratification by tumour type (papillary and 
follicular), showing that different histological types can have different genetic basis. This study 
seems to be the only one performed until now, concerning NHEJ and thyroid cancer. 
3. Conclusion  
Several reports have been published associating some SNPs in DNA repair genes with 
breast and thyroid cancer disease. Although relevant, the modifying effect of the majority of 
these SNPs in cell phenotype is still not understood and association studies are 
contradictory. This inconsistency might be due to different populations used, sample sizes, 
sample selection bias, genetic background and life style. Retrospective studies like these 
have to be interpreted with care and are difficult to draw meaningful practical conclusions 
from that can help directly patients with breast and thyroid cancer. In order to acquire more 
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powerful and accurate results several meta-analysis also have been published reviewing all 
studies made till publication date about a particular SNP and disease. Again, these reports 
need to be interpreted with caution, since many authors have study selection bias, including 
all cases of breast cancer, even the ones with BRCA1 and BRCA2 mutations carriers. 
Prospective studies and adequately selected meta-analysis should give further insight about 
the relevance of SNPs in breast and thyroid cancerigenesis.  
Although the real role of SNPs in cancerigenesis is not well established by the authors, the 
new era in cancer treatment and prevention lies in the ability to treat patients individually 
according their genetic constitution and the DNA repair status of their tumours. For that, is 
crucial to have specific knowledge about the polymorphisms carried by each patient and 
how these polymorphisms influences response to therapy.  
In fact, the existence of inter-individual variation influences response and survival rate 
following chemotherapy and radiation treatment of cancer. Standard cancer therapy 
involves the use of agents that themselves damage DNA with the ultimate goal of killing the 
cell. However, damaging the DNA does not always kill the cell, which is avoided by DNA 
repair pathways that remove the damage from DNA. Recent studies have suggested that the 
targeting of repair pathways by specific agents can result in effective killing of tumour cells 
(Li et al., 2010). DNA damage acquired from these treatments can initiate a number of 
cellular pathways involved in DNA repair, cell cycle control, metabolism and apoptosis 
(Bewick et al., 2011). If so, SNPs in genes of DNA repair may significantly affect its 
efficiency, clinical outcome and thus may help identify patients that can benefit from 
various treatments. Accordingly, new strategies for individualization of treatment in cancer 
patients are becoming an emerging issue. 
Due to a phenomenon known as linkage disequilibrium, the value of a SNP in the same 
chromosome could be associated with specific values in other SNPs nearby. Indeed, specific 
SNPs associations (tagSNPs) related with the toxicity/efficacy of DNA damaging 
chemotherapy, improve our ability to map SNPs in specific genes associated with 
chemotherapy resistance and assure a better clinical outcome for cancer patients. This 
approach seems to be of importance since it can associate haplotype blocks with cancer 
therapy with lesser resources (Anunciação et al., 2010; Frazer et al., 2007). 
Some SNPs in DNA repair genes have been reported as potential markers for individual 
susceptibility to breast (e.g. XRCC1; XRCC2 and XRCC3 genes polymorphisms) and thyroid 
(e.g. XRCC1; XRCC3 and RAD51 genes polymorphisms) cancers. However, the incoherent 
results don’t have enough strength to demonstrate the real role of those SNPs, at least with 
regards to breast and thyroid carcinomas. We think that genetic polymorphisms, 
particularly SNPs, may have low influence in breast and thyroid cancerigenesis, however, 
SNPs may be much more relevant in acquired resistance to chemotherapeutic agents. In fact, 
new strategies for individualization of treatment in cancer patients are becoming an 
emerging issue. This approach must be the best way to find a practical result and clinical use 
for association studies. The emergence of SNPs with important roles in cancer therapy is 
now the focus of our work. 
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